Coronavirus disease (COVID-19)
The European Medicines Agency (EMA) is contributing to global efforts to save lives during the COVID-19 pandemic by expediting the development and approval of safe and effective treatments and vaccines, supporting the continued availability of medicines in the European Union (EU), and providing reliable information to patients and healthcare professionals.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
On 30 January 2020, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern. On 11 March 2020, WHO characterised COVID-19 as a pandemic.
EMA aims to expedite the development of effective medicines and vaccines to fight and prevent the spread of COVID-19.
The Agency also aims to ensure that the assessment and monitoring of medicines are not disrupted so that patients in Europe continue to have access to high quality, safe and effective medicines for all their health needs during the pandemic.
The COVID-19 EMA pandemic Task Force is at the centre of the efforts to enable EMA, the European medicines regulatory network and the European Commission to take quick and coordinated regulatory action during the pandemic across all EU Member States.
EMA is continuously reviewing and adapting its measures as necessary.
COVID-19: latest updates
COVID-19 vaccines: key facts
Transparency: exceptional measures for COVID-19 medicines
Availability of medicines during COVID-19 pandemic
EMA’s governance during COVID-19 pandemic
COVID-19 vaccines: development, evaluation, approval and monitoring
Guidance for medicine developers and other stakeholders on COVID-19
Public-health advice during COVID-19 pandemic